AstraZeneca will use the new dPCR methylation assays for clinical research study. Credit: SAGA Diagnostics.

Swedish company Saga Diagnostics has signed an agreement with AstraZeneca for the development of new digital polymerase chain reaction (dPCR) assays.

Under the terms of the deal, Saga will develop new SAGAsafe dPCR assays to detect undisclosed methylated targets for evaluating tissue and liquid biopsy samples.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A patented improvement of dPCR, SAGAsafe enables an increased sensitivity of around 100-fold as compared to other rival methods.

It is part of Saga’s portfolio of ultrasensitive technologies, which also includes a personal monitoring technology for cancer burden, as well as minimal residual disease (MRD), called Sagasign.

AstraZeneca epigenomics, oncology translational medicine and oncology research and development director James Hadfield said: “We have chosen to partner with Saga because of the ultrasensitive performance of the SAGAsafe technology and possibility to custom-tailor highly complex dPCR assays to meet our desired analytical standards. We are excited about exploring this new area together with Saga.”

SAGAsafe can be utilised to determine the quantity of sequence variants in tissue samples and liquid biopsies such as blood plasma.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Using the technology, the denaturation state of input material can be determined to obtain accurate results.

Saga Diagnostics co-founder and chief operating officer Lao Saal said: “We are honoured that Dr Hadfield and his team have selected Saga and the SAGAsafe platform to develop ultrasensitive dPCR methylation assays for AstraZeneca’s clinical research study and are pleased to be working together again.”

In September, AstraZeneca and the clinical sequencing unit of Thermo Fisher Scientific partnered on the joint development of next-generation sequencing (NGS)-based companion diagnostics (CDx).

NGS-based CDx can be used for matching patients with new treatments for oncology and other diseases.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact